RAPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rapport Therapeutics Inc (RAPP) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show bullish momentum, the stock is currently overbought (RSI at 92.199), and the pre-market price is down 2.63%. The options data suggests bearish sentiment with a high Option Volume Put-Call Ratio of 4.0. Furthermore, the company has no revenue, is operating at a loss, and lacks recent positive news or significant financial catalysts. For a long-term investor, it would be prudent to wait for a better entry point or more concrete positive developments.
The stock shows bullish momentum with MACD above 0 and expanding positively, and moving averages (SMA_5 > SMA_20 > SMA_200) indicating an uptrend. However, RSI at 92.199 signals the stock is overbought, suggesting a potential pullback. Key resistance levels are at 38.493 and 40.599, with support at 35.086 and 31.679.
Analysts from Raymond James and Wells Fargo have initiated coverage with strong buy and overweight ratings, citing potential in RAP-219's Phase 2 readout for bipolar mania and focal onset seizures. This could be a long-term catalyst.
The stock is overbought (RSI 92.199), pre-market price is down 2.63%, and options data shows bearish sentiment. Additionally, the company has no revenue and is operating at a significant loss.
In Q4 2025, the company reported no revenue and a net loss of $33.76 million, though net income improved by 68.98% YoY. EPS increased to -0.72, up 26.32% YoY, but the company remains unprofitable.
Raymond James initiated coverage with a Strong Buy rating and a $66 price target, citing potential in RAP-219's Phase 2 readout for bipolar mania. Wells Fargo rated the stock Overweight with a $43 price target, highlighting 'best-in-category efficacy' potential in focal onset seizures.
